Press Release

G2GBio has the best subject matter experts in the field of the injectable drug development.

G2GBIO secures PK data for high-dose once-monthly dementia injectable – “Steady-state at 280mg”
2026.09.09
HIT 1254

G2GBIO secures PK data for high-dose once-monthly dementia injectable – “Steady-state at 280mg”


 

- ‘GB-5001’ 280 mg Phase 1 clinical trial, dosed at 4-week intervals, completed in Indonesia

- Steady state (constant blood drug concentration) reached from 3rd dose onward –Stable exposure confirmed at high doses

- 280 mg average blood concentration matches therapeutic effect range of ‘Aricept’ 10 mg

 

 

 

[by Ji, Yong Jun] G2GBIO has secured additional pharmacokinetic (PK) data supporting high-dose repeat administration of 'GB-5001' (development code), its investigational long-acting, once-monthly treatment for Alzheimer's disease. GB-5001 is being developed as an injectable formulation designed to replace daily oral donepezil with a dosing once every four weeks.

 

In a recent Phase 1 clinical trial conducted in Indonesia, G2GBIO confirmed stable drug exposure profiles following high-dose repeated administration of 280 mg. Based on the clinical data generated in Canada and Korea, the company plans to accelerate preparations for follow-up studies.

 

According to industry sources on September 8, G2GBIO recently completed a study in Indonesia evaluating repeated 280 mg doses of GB-5001 in healthy participants, securing pharmacokinetic and safety data. The Phase 1 clinical trial was conducted from August 2025 to April 2026, involving 28 healthy adults who received 280 mg of GB-5001 at four-week intervals.

 

The study showed that the drug reached a ‘steady state,’ in which drug concentration in the body remained stable, following the third 280 mg dose, with a consistent drug exposure profile maintained throughout repeated administration. In terms of safety, no serious adverse events (SAEs) were reported after repeated high-dose administration, while adverse drug reactions were minimal and predominantly ‘mild.’ G2GBIO highlighted that the candidate demonstrated favorable tolerability and safety despite repeated dosing at 280 mg.

 

G2GBIO explained that the findings were consistent with those from a previous GB-5001 140 mg repeated administration study conducted in Korea. In that study, participants received four 140 mg of GB-5001 at four-week intervals, similarly demonstrating a stable steady-state pharmacokinetic profile.

 

Dose-dependent drug exposure was also confirmed in an earlier Phase 1 clinical trial conducted in Canada. G2GBIO evaluated the safety, tolerability, and pharmacokinetics of single 70 mg, 140 mg, and 280 mg doses of GB-5001 in ‘healthy male’ volunteers. The results showed both maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) increased as the administered dose rose.

 

G2BIO explained that the combining findings from the Canadian single-dose trial and the repeated dose studies conducted in Korea and Indonesia demonstrated a consistent increase in drug exposure with escalating doses. The company added that no notable country- or race-related differences in pharmacokinetic profiles were observed across the three studies.

 

Based on the single- and repeated-dose data generated to date, G2GBIO plans to consult with relevant regulatory authorities on the direction of subsequent research and prepare for the next clinical trial. “Stable steady-state pharmacokinetic profiles were observed in both studies, with four 140 mg doses administered at four-week intervals in Korea and repeated high-dose administration of 280 mg evaluated in Indonesia. Mean steady-state blood concentrations remained in a range comparable to the therapeutic exposure achieved with 5 mg and 10 mg doses of Aricept (donepezil). Based on the findings secured to date, we will proceed with preparations for the next clinical trial,'" a company official said.